Angiotech, best known for formulating the paclitaxel that goes on Boston Scientific's drug-eluting stent, has has signed two orthopedics deals; it's acquired NeuColl Inc., a private developer of collagen-based biomaterials for orthopedic applications and has also allied with Orthovita Inc., which will distribute Angiotech's hemostatic biomaterial in orthopedics markets. These, together with a string of other acquisitions in the past year, have diversified Angiotech into interventional cardiology, vascular surgery, anti-adhesion in gynecological surgery, and orthopedics--apparently unrelated fields. That represents a great deal of diversity for a mid-sized company with limited resources, but all of the areas share a common theme. Beyond the drug-eluting stent, Angiotech believes that potentially hundreds of large markets exist where drugs can improve the performance of devices.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.